相关实验视频

Updated: Jan 8, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

[抑制O-GlcNAc转移酶可缓解自发肥胖小鼠肝脏病理变化]

Zi-Yang Zhang¹, Xin-Yu Long¹, Jia-Yi Zhang¹

¹Key Laboratory of Bovine Disease Control in Northeast China, Ministry of Agriculture and Rural Affairs, College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing 163319, China.

Sheng li xue bao : [Acta physiologica Sinica]

|December 22, 2025

概括

抑制O-GlcNAc转移酶 (OGT) 与OSMI-1减少肥胖小鼠的体重和肝脏质量. 通过降低OGT和脂解相关蛋白质的调节,OGT抑制改善了肝脏脂肪积累和病理变化.

科学领域:

生物化学生物化学
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

肥胖与肝脏病理和代谢功能障碍有关.
O-GlcNAc转移酶 (OGT) 在新陈代谢调节中发挥作用.
针对OGT可能为与肥胖相关的肝病提供治疗潜力.

研究的目的:

为了研究OGT抑制对自发肥胖小鼠肝脏病理学的影响.
评估OGT抑制对血清生物化学标记物和与脂解相关的蛋白质表达的影响.

主要方法:

实验小鼠接受了OGT抑制剂OSMI-1或对照组的治疗.
分析了肝脏组织和血清的OGT表达,脂解蛋白和病理变化 (HE,油红O,糖原,马森染色).
测量了血清生物化学指数,包括脂质概况.

主要成果:

治疗OSMI-1显著降低了体重,肝脏质量和肝脏O-GlcNAc水平.
血清标志物 (AST,ALT,TBA,LDH,TCHO,TRIG) 和脂质样本 (HDL-C,LDL-C) 显著下降.
肝脂滴积累,多核化和真空化减少,而糖原和原纤维含量发生了变化.

结论:

在肥胖小鼠中,OGT抑制有效地改善了异常血清指标,并减少了肝脏脂肪的积累.
用OSMI-1准OGT显示了减轻与肥胖相关的肝脏病理变化的潜力.

更多相关视频

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...